Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol | Zendy

T. Krueger | Zendy; Georg Schlieper | Zendy; Leon J. Schurgers | Zendy; T. Cornelis | Zendy; Mario Cozzolino | Zendy; J. Jacobi | Zendy; Michel Jadoul | Zendy; Markus Ketteler | Zendy; Lars Christian Rump | Zendy; Peter Stenvinkel | Zendy; Ralf Westenfeld | Zendy; A. Wiecek | Zendy; Sebastian Reinartz | Zendy; R.-D Hilgers | Zendy; J. Floege | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol

Author(s) -

T. Krueger,

Georg Schlieper,

Leon J. Schurgers,

T. Cornelis,

Mario Cozzolino,

J. Jacobi,

Michel Jadoul,

Markus Ketteler,

Lars Christian Rump,

Peter Stenvinkel,

Ralf Westenfeld,

A. Wiecek,

Sebastian Reinartz,

R.-D Hilgers,

J. Floege

Publication year - 2013

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gft459

Subject(s) - medicine , matrix gla protein , calcification , vitamin d and neurology , vitamin k2 , vitamin , hemodialysis , calcinosis , endocrinology , ectopic calcification

Patients on haemodialysis (HD) exhibit increased cardiovascular mortality associated with accelerated vascular calcification (VC). VC is influenced by inhibitors such as matrix Gla protein (MGP), a protein activated in the presence of vitamin K. HD patients exhibit marked vitamin K deficiency, and supplementation with vitamin K reduces inactive MGP levels in these patients. The VitaVasK trial analyses whether vitamin K1 supplementation affects the progression of coronary and aortic calcification in HD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research